Seeking to topple long-standing obstacles to drug innovation in Japan, pharmaceutical industry leaders in the country have outlined a slate of steps they propose the government take to foster research and development of new products, trim regulations and approval times, and speed distribution.
Top among the proposals are bolstering government investment in collaborations between academics and drug startups and making the government’s system of establishing drug price health insurance reimbursements more predictable and transparent.
The pharma industry proposals were shared with major political parties in Japan and with regulatory agencies over the summer. They are geared toward bolstering pharmaceutical innovation and the drug development sector of the economy by increasing efficiency, reducing investment risks, and making it easier for firms to build human resources.